Tuesday, July 29, 2014

Research Studies

Human Subjects Protection Training
Participate in Research
Researchers
Research Studies 


btqlogo2013.jpg

 

Bitch to Quit Smoking Cessation Research Study

Bitch to Quit (BTQ) is proud to be one of the first studies in the nation focusing on smoking in the LGBTQ community! The study is currently seeking adult lesbian, gay, bisexual, transgender, and queer (LGBTQ) smokers who are interested in quitting smoking. The study includes 6 group-counseling sessions, 8 weeks of nicotine replacement therapy, and compensation for time and travel!

For more information, please
e-mail:
 BTQ@howardbrown.org call 773-388-8868.

 

Project Adhere

Howard Brown Health Center is the study site for Project Adhere, a research intervention designed to understand the quit smoking and medication adherence needs of HIV+ African American men who have sex with men (MSM). This project is a natural extension of Bitch to Quit, the larger quit smoking research program for the LGBTQ community. Currently, we are seeking African American men for two 90-minute focus groups to assess the quit smoking and medication adherence needs for this community to develop the intervention. Participants will receive $25 for each focus group.

Eligibility criteria include:
1) Identify as African American or Black
2) Identify as a man who has sex with other men
3) be HIV-positive
4) be a smoker
and
5) have a current antiretroviral (HIV medication) prescription.

If you are interested in participating, please contact Kyle Jones in the Research Department at (773) 388-1600 ext. 8899 or KyleJ@howardbrown.org.

 

Gilead GS-US-292-1249

Gilead GS-US-292-1249 is a Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobistat/Emtricitabine/Tenofvir Alafenamide Single-Tablet Regimen in HIV-1/ Hepatitis B Co-infected Adults. Eligible participants receive study medication and associated labs at no charge and are compensated for time. The Principal Investigator (PI) for this study is Dr. Catherine Creticos, MD.For more information, please contact Kenyetta Drummond at KenyettaD@howardbrown.org or 773-572-5116.

 

Gilead GS-US-292-0117
Gilead GS-US-292-0117 is an Phase 3, Two-Part Study to Evaluate the Efficacy of Tenofovir Alafenmide versus Placebo Added to a Failing Regimen Followed by Treatment with Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults. Eligible participants receive study medication and associated labs at no charge and are compensated for time. The Principal Investigator (PI) for this study is Dr. Catherine Creticos, MD.

For more information, please contact Kenyetta Drummond at
 KenyettaD@howardbrown.org or 773-572-5116. 

 

Gilead GS-US-292-0119
Gilead GS-US-292-0119 in an Phase 3 Open-Label Study to Evaluate Switching from Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenefovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults. Eligible participants receive study medication and associated labs at no charge and are compensated for time. The Principal Investigator (PI) for this study is Dr. Catherine Creticos, MD.

For more information, please contact Kenyetta Drummond at KenyettaD@howardbrown.org or 773-572-5116.

 

HPV Prevalence Study

HBHC is proud to be a recruitment site for a study on human papillomavirus (HPV) in collaboration with the Centers for Disease Control and Prevention, the University of Kentucky, and the University of California at Los Angeles. With the help of over 150 HBHC clients thus far, staff in our Research Department are continuing work to determine the prevalence of human papillomavirus (HPV) among a group of MSM aged 18-26 and assess knowledge, attitudes, and practices regarding HPV vaccination within our community.

For more information, please feel free to contact John Cesario at JohnC@howardbrown.org.